Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Northwest Biotherapeutics ( (NWBO) ) has shared an update.
On October 24, 2025, Northwest Biotherapeutics, Inc. completed the acquisition of Advent BioServices Ltd., a U.K.-based CDMO that had been providing product development, manufacturing, cryostorage, and distribution services for the company’s DCVax immunotherapy platform. Advent became a wholly owned subsidiary, with consideration structured as approximately $1.9 million in purchase price plus about $8.3 million in settlement of pre-existing payables, payable in installments over two years with interest accruing at 7.5% on unpaid balances.
At closing, Northwest Biotherapeutics also recovered 12 million shares of its common stock and 5.5 million stock options previously issued to Advent as service compensation, retiring the shares to treasury and canceling the options, which reduces potential dilution for existing shareholders. The deal, a related-party transaction due to CEO Linda Powers’ control of the seller, was approved under the company’s related-party policies, and the company obtained a regulatory waiver allowing it not to provide certain historical and pro forma financial statements related to the acquisition.
More about Northwest Biotherapeutics
Northwest Biotherapeutics, Inc. is a biotechnology company focused on developing immunotherapy products, including its DCVax product platform, for the treatment of cancer. The company utilizes contract development and manufacturing services to support product development, manufacturing, cryostorage, and distribution of its DCVax portfolio, particularly its DCVax-L product candidate.
Average Trading Volume: 2,423,789
Technical Sentiment Signal: Sell
Current Market Cap: $313.2M
For detailed information about NWBO stock, go to TipRanks’ Stock Analysis page.